365 related articles for article (PubMed ID: 25749475)
1. Faldaprevir for the treatment of hepatitis C.
Kanda T; Yokosuka O; Omata M
Int J Mol Sci; 2015 Mar; 16(3):4985-96. PubMed ID: 25749475
[TBL] [Abstract][Full Text] [Related]
2. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
Jensen DM; Asselah T; Dieterich D; Foster GR; Sulkowski MS; Zeuzem S; Mantry P; Yoshida EM; Moreno C; Ouzan D; Wright M; Morano LE; Buynak R; Bourlière M; Hassanein T; Nishiguchi S; Kao JH; Omata M; Paik SW; Wong DK; Tam E; Kaita K; Feinman SV; Stern JO; Scherer J; Quinson AM; Voss F; Gallivan JP; Böcher WO; Ferenci P
Ann Hepatol; 2016; 15(3):333-49. PubMed ID: 27049487
[TBL] [Abstract][Full Text] [Related]
3. Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.
Berger KL; Scherer J; Ranga M; Sha N; Stern JO; Quinson AM; Kukolj G
Antimicrob Agents Chemother; 2015 Oct; 59(10):6017-25. PubMed ID: 26195509
[TBL] [Abstract][Full Text] [Related]
4. Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results.
Zeuzem S; Asselah T; Angus P; Zarski JP; Larrey D; Müllhaupt B; Gane E; Schuchmann M; Lohse AW; Pol S; Bronowicki JP; Roberts S; Arasteh K; Zoulim F; Heim M; Stern JO; Nehmiz G; Kukolj G; Böcher WO; Mensa FJ
Antivir Ther; 2013; 18(8):1015-9. PubMed ID: 23558093
[TBL] [Abstract][Full Text] [Related]
5. Faldaprevir for the treatment of genotype-1 hepatitis C virus.
Agarwal K; Barnabas A
Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):277-88. PubMed ID: 25633983
[TBL] [Abstract][Full Text] [Related]
6. SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.
Dieterich D; Asselah T; Guyader D; Berg T; Schuchmann M; Mauss S; Ratziu V; Ferenci P; Larrey D; Maieron A; Stern JO; Ozan M; Datsenko Y; Böcher WO; Steinmann G
Antimicrob Agents Chemother; 2014 Jun; 58(6):3429-36. PubMed ID: 24709256
[TBL] [Abstract][Full Text] [Related]
7. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.
Sulkowski MS; Asselah T; Lalezari J; Ferenci P; Fainboim H; Leggett B; Bessone F; Mauss S; Heo J; Datsenko Y; Stern JO; Kukolj G; Scherer J; Nehmiz G; Steinmann GG; Böcher WO
Hepatology; 2013 Jun; 57(6):2143-54. PubMed ID: 23359516
[TBL] [Abstract][Full Text] [Related]
8. Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
Berger KL; Sarrazin C; Nelson DR; Scherer J; Sha N; Marquis M; Côté-Martin A; Vinisko R; Stern JO; Mensa FJ; Kukolj G
PLoS One; 2016; 11(8):e0160668. PubMed ID: 27494410
[TBL] [Abstract][Full Text] [Related]
9. Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
Dieterich D; Nelson M; Soriano V; Arastéh K; Guardiola JM; Rockstroh JK; Bhagani S; Laguno M; Tural C; Ingiliz P; Jain MK; Stern JO; Manero M; Vinisko R; Kort J;
AIDS; 2015 Mar; 29(5):571-81. PubMed ID: 25710287
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection.
Nishiguchi S; Sakai Y; Kuboki M; Tsunematsu S; Urano Y; Sakamoto W; Tsuda Y; Steinmann G; Omata M
Liver Int; 2014 Jan; 34(1):78-88. PubMed ID: 23944720
[TBL] [Abstract][Full Text] [Related]
11. HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.
Sarrazin C; Manns M; Calleja JL; Garcia-Samaniego J; Forns X; Kaste R; Bai X; Wu J; Stern JO
PLoS One; 2016; 11(12):e0168544. PubMed ID: 28030579
[TBL] [Abstract][Full Text] [Related]
12. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
Berger KL; Triki I; Cartier M; Marquis M; Massariol MJ; Böcher WO; Datsenko Y; Steinmann G; Scherer J; Stern JO; Kukolj G
Antimicrob Agents Chemother; 2014; 58(2):698-705. PubMed ID: 24217701
[TBL] [Abstract][Full Text] [Related]
13. HCV direct-acting antiviral agents: the best interferon-free combinations.
Schinazi R; Halfon P; Marcellin P; Asselah T
Liver Int; 2014 Feb; 34 Suppl 1(Suppl 1):69-78. PubMed ID: 24373081
[TBL] [Abstract][Full Text] [Related]
14. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
Welch NM; Jensen DM
Liver Int; 2015 Jan; 35 Suppl 1():11-7. PubMed ID: 25529082
[TBL] [Abstract][Full Text] [Related]
15. Faldaprevir and deleobuvir for HCV genotype 1 infection.
Zeuzem S; Soriano V; Asselah T; Bronowicki JP; Lohse AW; Müllhaupt B; Schuchmann M; Bourlière M; Buti M; Roberts SK; Gane EJ; Stern JO; Vinisko R; Kukolj G; Gallivan JP; Böcher WO; Mensa FJ
N Engl J Med; 2013 Aug; 369(7):630-9. PubMed ID: 23944300
[TBL] [Abstract][Full Text] [Related]
16. STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
Ferenci P; Asselah T; Foster GR; Zeuzem S; Sarrazin C; Moreno C; Ouzan D; Maevskaya M; Calinas F; Morano LE; Crespo J; Dufour JF; Bourlière M; Agarwal K; Forton D; Schuchmann M; Zehnter E; Nishiguchi S; Omata M; Kukolj G; Datsenko Y; Garcia M; Scherer J; Quinson AM; Stern JO;
J Hepatol; 2015 Jun; 62(6):1246-55. PubMed ID: 25559324
[TBL] [Abstract][Full Text] [Related]
17. Faldaprevir for the treatment of hepatitis C.
Campagna D; Demma S
Drugs Today (Barc); 2015 May; 51(5):289-301. PubMed ID: 26097902
[TBL] [Abstract][Full Text] [Related]
18. Emerging therapies for hepatitis C.
Kim DY; Ahn SH; Han KH
Gut Liver; 2014 Sep; 8(5):471-9. PubMed ID: 25228970
[TBL] [Abstract][Full Text] [Related]
19. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
20. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
Tornai I
Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
